AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The EMA will continue to investigate whether AstraZeneca's (AZN) COVID-19 vaccine was the cause of the blood clot events or if these were due to other reasons.

AstraZeneca (AZN) COVID-19 Shot Faces Doubts Over Blood Clots

The World Health Organization said Wednesday that the benefits of AstraZeneca's COVID-19 vaccine still outweigh the risks and it should continue to be administered, after several countries in Europe halted vaccinations over concerns about blood clots. U.S.-listed shares of AstraZeneca were down 1.5% in trading on Wednesday.

WHO says to keep administering AstraZeneca's vaccine

According to a Phase 1b-2 trial published in the New England Journal of Medicine, the two-dose COVID-19 vaccine developed by Oxford University / AstraZeneca Plc (NASDAQ: AZN) was ineffective against mild-to-moderate infections caused due to mutated virus strain in South Africa, dubbed as B.1.351 variant. What Happened: The study was led by scientists at the South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit.

AstraZeneca's COVID-19 Vaccine Has No Efficacy Against South African Virus Strain, Study Shows

Novavax

Pfizer

These COVID Stocks Could Be Hurt by a Global Raw Material Shortage

Will recent troubles weigh on AstraZeneca stock?

Some Countries Suspended AstraZeneca's COVID Vaccine. Here's What Investors Need to Know.

France and Italy say they are ready to quickly restart inoculation programs with the AstraZeneca vaccine if regulators confirm it's still safe to use.

Italy and France ready to restart AstraZeneca vaccinations if regulators give the green light

Alexion Pharma

AstraZeneca stock jumped Tuesday after the company reaffirmed its plan to acquire Alexion Pharmaceuticals in the third quarter, even as more European countries suspended use of its Covid vaccine. The post AstraZeneca Pops On Alexion Buyout Despite Mounting Covid Vaccine Doubt appeared first on Investor's Business Daily.

AstraZeneca Pops On Alexion Buyout Despite Mounting Covid Vaccine Doubt

European Medical Agency (EMA) will release its investigation results on Thursday afternoon into incidents of bleeding, blood clots, and low platelet counts after AstraZeneca Plc's (NASDAQ: AZN) coronavirus vaccine, reports Reuters. What Happened: EMA Executive Director Emer Cooke said there was no indication that the incidents, which she called “very rare”, but that experts were assessing that possibility.

EMA Investigating Coagulation Cases After Several European Countries Pause AZN Shot; Findings Expected This Thursday: Reuters

The European Medicines Agency reiterated its findings as Sweden became the latest country to pause inoculations with the AstraZeneca Covid-19 shot.

EU Regulator Says ‘No Indication' AstraZeneca Vaccine Causes Blood Clots

AstraZeneca PLC (LON:AZN) was upgraded to ‘buy' from ‘hold' by Jefferies as analysts believe pipeline catalysts and new launches should aid recovery of the shares. The US investment bank hiked the target price by 7% to 8850p as the risk-reward is significantly more positive, given the pharma giant's “compelling” growth profile within EU Pharma.

AstraZeneca upgraded to ‘buy' by Jefferies as pipeline should aid recovery of shares

Shares in AstraZeneca PLC (LON:AZN) got a boost on Tuesday as the coronavirus (COVID-19) vaccine developed with Oxford University will be reviewed by experts worldwide. The World Health Organization (WHO) and the European Medicines Agency (EMA) will hold separate meetings after 11 EU countries halted the rollout of the jab, alongside Thailand, Venezuela and Indonesia.

AstraZeneca COVID-19 vaccine to be reviewed by WHO, EU regulator

AstraZeneca shares could gain at least another 25% as upcoming COVID-19 vaccine data should provide a buying opportunity, says Jefferies, which also foresees the strategic merits of the drug maker's pending acquisition of Alexion Pharmaceuticals become more "widely appreciated". AstraZeneca's "impressive revenue and profit trajectory is compelling" relative to its European pharmaceutical industry peers, said Jefferies in a research note Tuesday in which it raised its rating to buy from hold. The price target was also increased, to $61.50 from $56.

AstraZeneca stock holds 26% upside on 'multitude of pipeline catalysts', says Jefferies

The European Medicines Agency is "firmly convinced" the vaccine's benefits outweighed the risk of side effects.

Sweden halts AstraZeneca vaccine use as EMA says ‘no indication' shot causes blood clots

AstraZeneca said its experimental, long-acting antibody-based Covid-19 combination treatment aims to protect those who aren't able to be vaccinated.

AstraZeneca to Supply Extra 500,000 Doses of Covid-19 Treatment to U.S.

Most medicine regulators have advised against the temporary ban, which will delay already-slow vaccination campaigns on the continent.

Europe's shelving of AstraZeneca shot delays further its troubled vaccination campaigns

The World Health Organization said that global distribution of the AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine remains unruffled, though much of Europe has stopped using the shot after reports of blood clots in some people shortly after immunization, reports Washington Post. The EMA has not recommended that authorities suspend the use and WHO also came out to advise against halting vaccinations.

Suspensions In Europe Will Not Disturb AstraZeneca Vaccine's Global Roll Out: Report

Decisions by at least 16 countries to suspend use of the AstraZeneca vaccine is "baffling", "reckless" and "political", experts have said. A growing list of nations has pulled the shot from use, with most of the biggest nations of Europe deciding to stop on Tuesday.

The growing list of countries suspending use of the AstraZeneca vaccine may be doing much more harm than good, experts say

AstraZeneca, international regulators, and numerous experts all say the vaccine is safe and there is no evidence it is linked to blood clots.

AstraZeneca Vaccine: Here's What To Expect As Europe's Medicines Regulator And The WHO Meet To Review Shot

Late-stage trial data of AstraZeneca's coronavirus vaccine might not look good—and that's a good opportunity to buy the Anglo-Swedish drug company, according to an analyst note released on Tuesday.

AstraZeneca Trial Data May Not Be Impressive, Setting Up A Buying Opportunity, Says Jefferies

AZD7442 is being evaluated for the prevention and treatment of COVID-19 in late-stage trials in more than 9,000 participants around the world.

AstraZeneca to supply U.S. with extra 500,000 doses of COVID-19 antibody-based cocktail

As Europe faces a third wave of Covid-19, the list of countries that have banned the AstraZeneca vaccine is getting longer.

Which Countries Have Stopped Using The AstraZeneca Vaccine? [Infographic]

Experts say the decision by some European countries to suspend use of the AstraZeneca/University of Oxford Covid shot could be damaging.

'The damage is done': Europe's caution over AstraZeneca vaccine could have far-reaching consequences

AstraZeneca PLC (LON:AZN) got a boost on Tuesday as the COVID-19 vaccine developed with Oxford University will be reviewed by experts worldwide. The World Health Organization (WHO) and the European Medicines Agency (EMA) will hold separate meetings after 11 EU countries halted the rollout of the jab, alongside Thailand, Venezuela and Indonesia.

AstraZeneca gets boost as WHO, EU regulator start reviews of COVID-19 vaccine

Two additional countries opted to suspend the use of the AstraZeneca vaccine in Europe on Tuesday as regulators proceed with a new review into its side effects.

More European countries suspend AstraZeneca shot as regulators review its side effects

AstraZeneca was upgraded to buy from hold at Jefferies, and its price target lifted to 8850 pence ($61.05 per U.S.-listed share) from 8250 pence. Analysts led by Peter Welford said AstraZeneca's "impressive" revenue and profit trajectory is compelling relative to European pharma peers, and the approaching close of the Alexion acquisition will make the deal's merits more widely appreciated.

News for AstraZeneca Stock (AZN)